MedTrace Logo

HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy

NCT07312045 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2025-12-31

No results posted yet for this study

Summary

This observational clinical study aims to investigate the relationship between the HALP score (Hemoglobin × Albumin × Lymphocyte / Platelet), several blood-based inflammatory indices (including NLR, PLR, LMR, and SII), and salivary MMP-8 levels in individuals with periodontal health, gingivitis, and stage III/IV periodontitis. The study also evaluates how these biomarkers relate to healing following non-surgical periodontal therapy.

A total of 180 participants aged 18-65 years will be included: 50 healthy individuals, 50 patients with gingivitis, and 80 patients with stage III/IV periodontitis. All participants will undergo periodontal clinical examination and provide blood and saliva samples at baseline. Individuals in the gingivitis and periodontitis groups will receive standard non-surgical periodontal treatment (full-mouth debridement) and will return for a 3-month follow-up visit, where periodontal measurements will be repeated. In the periodontitis group, an additional blood sample will be collected at the 3-month follow-up visit.

The primary objective is to determine whether baseline HALP score, systemic inflammatory indices, and salivary MMP-8 levels differ between participants who show good versus poor healing after treatment. Secondary objective include comparing biomarker levels across periodontal status groups. The findings may contribute to early prediction of treatment response and personalized periodontal care.

Conditions

  • Periodontal Diseases
  • Periodontitis
  • Gingivitis; Chronic

Interventions

PROCEDURE

Non-surgical Periodontal Therapy

Standard full-mouth supra- and subgingival debridement performed in a single session, followed by oral hygiene instructions.

Sponsors & Collaborators

  • Erzincan Binali Yildirim Universitesi

    collaborator OTHER

  • Ömer Faruk Okumuş

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-25
Primary Completion
2026-11-25
Completion
2026-11-25

Countries

  • Turkey (Türkiye)

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07312045 on ClinicalTrials.gov